Answers are grounded in this paper and cite their sources.
Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.
No takes yet. Share an insight, caveat, or question.
Lingaraj et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: